QT prolongation by ranitidine in hypokalemia and arrhythmogen provoked rat heart

Sanmoy Karmakar, Md Asif Ali, Rammohan Bera, Hindol Mazumdar, Tuhinadri Sen
2017 Vascular Diseases and Therapeutics  
Drugs with low arrhythmogenic tendencies fail to overcome the threshold to prolong QT interval and are ruled as safe. However, at provoked conditions these drugs might have the possibility to precipitate arrhythmia. Although small yet QT prolongation capability of such drugs must be investigated. The threshold required to prolong QT was attenuated using chronic dose of furosemide and clarithromycin. Once attenuated, QT prolongation capability of ranitidine was explored. Furosemide 10mg.kg -1 IP
more » ... emide 10mg.kg -1 IP on co-administration with Clarithromycin 70mg.kg -1 orally for seven day manifested QTc interval at par with that of self-control group. A significant drop in serum potassium level was observed. In test groups, Furosemide 10mg.kg -1 + Clarithromycin 70 mg.kg -1 & Ranitidine 25 mg.kg -1 (once daily) and Furosemide 10mg.kg -1 + Clarithromycin 70 mg.kg -1 & Ranitidine 25 mg.kg -1 (Twice daily) the QTc prolongation compared to self control group was +28.0 % and +55.3 %, respectively. In the later group, the QT interval was observed to increase more than half the RR interval on ECG, a clinical indicator of cardiac emergency. Marked change in serum potassium level was also observed in the test groups. When Ranitidine alone was administered twice daily for seven days, no significant change in QTc interval was observed. Attenuation of the QT interval prolongation threshold exacerbates slightest QT prolongation tendencies and hence determine arrhythmogenic tendency of test drug. This model may be implied in the assessment of cardio-safety of drugs.
doi:10.15761/vdt.1000125 fatcat:jrk4q2t3tnevzkglj4ftl2amva